NCT00612677View on ClinicalTrials.gov

Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Lung Cancer
Interventions
DRUG

Oxaliplatin

Dose Regimen: 120 mg/m\^2 on Days 1 every 21 days

DRUG

Pemetrexed

Dose Regimen: 500 mg/m\^2 on Days 1 every 21 days

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00612677 - Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem | Biotech Hunter | Biotech Hunter